Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Mar 13;9(3):e025495.
doi: 10.1136/bmjopen-2018-025495.

Randomised controlled trial of a video intervention and behaviour contract to improve medication adherence after renal transplantation: the VECTOR study protocol

Affiliations

Randomised controlled trial of a video intervention and behaviour contract to improve medication adherence after renal transplantation: the VECTOR study protocol

Holly Mansell et al. BMJ Open. .

Abstract

Introduction: Non-adherence after kidney transplantation contributes to increased rejections, hospitalisations and healthcare expenditures. Although effective adherence interventions are sorely needed, increasing education and support to transplant recipients demands greater use of care providers' time and resources in a healthcare system that is stretched. The objective of this clinical trial is to determine the effectiveness of an electronically delivered video series and adherence behaviour contract on improving medication adherence to immunosuppressant medications.

Methods and analysis: A multicentre, parallel arm, randomised controlled trial will be conducted with four sites across North America (Saskatoon, Calgary, Halifax, Chicago). Adult patients will be randomised (1:1) to either the intervention (ie, home-based video education +behaviour contract plus usual care) or usual care alone. De novo transplant recipients will be enrolled prior to their hospital discharge and will be provided with electronic access to the video intervention (immediately) and adherence contract (1 month post-transplant). Follow-up electronic surveys will be provided at 3 and 12 months postenrolment. The primary outcome will be adherence at 12 months post-transplant, as measured by self-report Basel Assessment of Adherence to Immunosuppressive medications and immunosuppressant levels. Secondary outcomes include the difference in knowledge score between the intervention and control in groups (measured by the Kidney Transplant Understanding Tool); differences in self-efficacy (Generalised Self-efficacy Scale), Beliefs of Medicine Questionnaire (BMQ), quality of life (Short Form-12), patient satisfaction and cost utilisation. The study aims to recruit at least 200 participants across participating sites.

Ethics and dissemination: Ethical approval was obtained from the University of Saskatchewan Behavioural Ethics Committee (Beh 18-63), and all patients provide informed consent prior to participating. This educational intervention aims to improve information retention and self-efficacy, leading to improved medication adherence after kidney transplantation, at low cost, with little impact to existing healthcare personnel. If proven beneficial, delivery can be easily implemented into standard of care.

Trial registration number: NCT03540121; Pre-results.

Keywords: adherence; adherence contract; patient education; patient-oriented research; transplant knowledge, randomized trial; video.

PubMed Disclaimer

Conflict of interest statement

Competing interests: HM, NR, RM and AS developed the video intervention used in this project.

Figures

Figure 1
Figure 1
Depicts a flow chart describing the study process. SSRL, Social Sciences Research Laboratory.

References

    1. Wolfe RA, Ashby VB, Milford EL, et al. . Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1999;341:1725–30. 10.1056/NEJM199912023412303 - DOI - PubMed
    1. Oniscu GC, Brown H, Forsythe JL. Impact of cadaveric renal transplantation on survival in patients listed for transplantation. J Am Soc Nephrol 2005;16:1859–65. 10.1681/ASN.2004121092 - DOI - PubMed
    1. Abecassis M, Bartlett ST, Collins AJ, et al. . Kidney transplantation as primary therapy for end-stage renal disease: a National Kidney Foundation/Kidney Disease Outcomes Quality Initiative (NKF/KDOQITM) conference. Clin J Am Soc Nephrol 2008;3:471–80. 10.2215/CJN.05021107 - DOI - PMC - PubMed
    1. Halloran PF. Immunosuppressive drugs for kidney transplantation. N Engl J Med Overseas Ed 2004;351:2715–29. 10.1056/NEJMra033540 - DOI - PubMed
    1. Dew MA, DiMartini AF, De Vito Dabbs A, et al. . Rates and risk factors for nonadherence to the medical regimen after adult solid organ transplantation. Transplantation 2007;83:858–73. 10.1097/01.tp.0000258599.65257.a6 - DOI - PubMed

Publication types

Substances

Associated data